JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Highlights from the second day included BillionToOne's 2024 revenue spike and CareDx's plan to expand indications for its transplant tests.
JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More
Highlights from the first day included Exact Sciences' plan to launch three new cancer tests in 2025 and Qiagen's sample prep launch plans for 2026.
The acquisition of genetic testing firm Ambry will open up new markets for Tempus, which is looking beyond the oncology field.
Quanterix to Acquire Akoya Biosciences
The deal will integrate Akoya's spatial biology capabilities with Quanterix's biomarker-detection tools for ultra-sensitive detection of protein biomarkers in blood and tissue.
Executives also provided additional information on the firm's Q4 2024 financial performance.
Clinical customers helped Illumina place 91 NovaSeq X instruments in the fourth quarter. CFO Ankur Dhingra said many planned to use them for MRD testing.
The firm reported approximately $60 million in revenues in 2024, more than double the amount it recorded in the prior year.
Truveta Genome Project Launches With $320M Investment From Regeneron, Illumina, Health Systems
The initiative aims to generate genetic data on tens of millions of volunteers, creating the largest and most diverse database of genotypic and phenotypic information available.